Kevan Shokat

Ziyang Zhang

Charles Craik

Peter Rohweder

Daniel Green

BREAKING NEWS!

Monoclonal antibody target engagement is controllable with the presence or absence of small molecule KRas G12C inhibitors


Hap10Bio technologies offer the promise of treating resistance to covalent inhibitors of oncoproteins



From the UCSF Laboratories of Charles Craik and Kevan Shokat, together with Ziyang Zhang and Peter Rohweder

(click pictures for bios and publication)